Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2021-09-11 04:06:00 UTC |
---|
Update Date | 2021-09-26 23:00:33 UTC |
---|
HMDB ID | HMDB0249583 |
---|
Secondary Accession Numbers | None |
---|
Metabolite Identification |
---|
Common Name | Canertinib |
---|
Description | Canertinib, also known as CI-1033, belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups. Based on a literature review very few articles have been published on Canertinib. This compound has been identified in human blood as reported by (PMID: 31557052 ). Canertinib is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Canertinib is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
---|
Structure | FC1=C(Cl)C=C(NC2=NC=NC3=CC(OCCCN4CCOCC4)=C(NC(=O)C=C)C=C23)C=C1 InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29) |
---|
Synonyms | Value | Source |
---|
CI-1033 | ChEBI | Canertinib | MeSH |
|
---|
Chemical Formula | C24H25ClFN5O3 |
---|
Average Molecular Weight | 485.938 |
---|
Monoisotopic Molecular Weight | 485.162995603 |
---|
IUPAC Name | N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide |
---|
Traditional Name | canertinib |
---|
CAS Registry Number | Not Available |
---|
SMILES | FC1=C(Cl)C=C(NC2=NC=NC3=CC(OCCCN4CCOCC4)=C(NC(=O)C=C)C=C23)C=C1 |
---|
InChI Identifier | InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29) |
---|
InChI Key | OMZCMEYTWSXEPZ-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Diazanaphthalenes |
---|
Sub Class | Benzodiazines |
---|
Direct Parent | Quinazolinamines |
---|
Alternative Parents | |
---|
Substituents | - Quinazolinamine
- N-arylamide
- Aniline or substituted anilines
- Alkyl aryl ether
- Halobenzene
- Fluorobenzene
- Aminopyrimidine
- Chlorobenzene
- Pyrimidine
- Aryl chloride
- Imidolactam
- Benzenoid
- Morpholine
- Oxazinane
- Monocyclic benzene moiety
- Aryl halide
- Aryl fluoride
- Heteroaromatic compound
- Acrylic acid or derivatives
- Amino acid or derivatives
- Carboxamide group
- Tertiary aliphatic amine
- Tertiary amine
- Secondary carboxylic acid amide
- Secondary amine
- Oxacycle
- Carboxylic acid derivative
- Azacycle
- Ether
- Dialkyl ether
- Organohalogen compound
- Organic nitrogen compound
- Organic oxygen compound
- Amine
- Carbonyl group
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Organochloride
- Organofluoride
- Organonitrogen compound
- Organooxygen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Canertinib,1TMS,isomer #1 | C=CC(=O)NC1=CC2=C(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C)N=CN=C2C=C1OCCCN1CCOCC1 | 4026.4 | Semi standard non polar | 33892256 | Canertinib,1TMS,isomer #1 | C=CC(=O)NC1=CC2=C(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C)N=CN=C2C=C1OCCCN1CCOCC1 | 3640.8 | Standard non polar | 33892256 | Canertinib,1TMS,isomer #1 | C=CC(=O)NC1=CC2=C(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C)N=CN=C2C=C1OCCCN1CCOCC1 | 5518.9 | Standard polar | 33892256 | Canertinib,1TMS,isomer #2 | C=CC(=O)N(C1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCOCC1)[Si](C)(C)C | 3938.0 | Semi standard non polar | 33892256 | Canertinib,1TMS,isomer #2 | C=CC(=O)N(C1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCOCC1)[Si](C)(C)C | 3584.3 | Standard non polar | 33892256 | Canertinib,1TMS,isomer #2 | C=CC(=O)N(C1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCOCC1)[Si](C)(C)C | 5624.4 | Standard polar | 33892256 | Canertinib,2TMS,isomer #1 | C=CC(=O)N(C1=CC2=C(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C)N=CN=C2C=C1OCCCN1CCOCC1)[Si](C)(C)C | 3775.9 | Semi standard non polar | 33892256 | Canertinib,2TMS,isomer #1 | C=CC(=O)N(C1=CC2=C(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C)N=CN=C2C=C1OCCCN1CCOCC1)[Si](C)(C)C | 3466.3 | Standard non polar | 33892256 | Canertinib,2TMS,isomer #1 | C=CC(=O)N(C1=CC2=C(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C)N=CN=C2C=C1OCCCN1CCOCC1)[Si](C)(C)C | 5025.3 | Standard polar | 33892256 | Canertinib,1TBDMS,isomer #1 | C=CC(=O)NC1=CC2=C(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C(C)(C)C)N=CN=C2C=C1OCCCN1CCOCC1 | 4218.4 | Semi standard non polar | 33892256 | Canertinib,1TBDMS,isomer #1 | C=CC(=O)NC1=CC2=C(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C(C)(C)C)N=CN=C2C=C1OCCCN1CCOCC1 | 3794.0 | Standard non polar | 33892256 | Canertinib,1TBDMS,isomer #1 | C=CC(=O)NC1=CC2=C(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C(C)(C)C)N=CN=C2C=C1OCCCN1CCOCC1 | 5481.4 | Standard polar | 33892256 | Canertinib,1TBDMS,isomer #2 | C=CC(=O)N(C1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCOCC1)[Si](C)(C)C(C)(C)C | 4134.4 | Semi standard non polar | 33892256 | Canertinib,1TBDMS,isomer #2 | C=CC(=O)N(C1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCOCC1)[Si](C)(C)C(C)(C)C | 3775.4 | Standard non polar | 33892256 | Canertinib,1TBDMS,isomer #2 | C=CC(=O)N(C1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN1CCOCC1)[Si](C)(C)C(C)(C)C | 5584.2 | Standard polar | 33892256 | Canertinib,2TBDMS,isomer #1 | C=CC(=O)N(C1=CC2=C(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C(C)(C)C)N=CN=C2C=C1OCCCN1CCOCC1)[Si](C)(C)C(C)(C)C | 4147.8 | Semi standard non polar | 33892256 | Canertinib,2TBDMS,isomer #1 | C=CC(=O)N(C1=CC2=C(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C(C)(C)C)N=CN=C2C=C1OCCCN1CCOCC1)[Si](C)(C)C(C)(C)C | 3779.3 | Standard non polar | 33892256 | Canertinib,2TBDMS,isomer #1 | C=CC(=O)N(C1=CC2=C(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C(C)(C)C)N=CN=C2C=C1OCCCN1CCOCC1)[Si](C)(C)C(C)(C)C | 4991.8 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Canertinib GC-MS (Non-derivatized) - 70eV, Positive | splash10-0zfr-9305500000-42b0ec2c269a58f9e7f2 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Canertinib GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Canertinib 10V, Positive-QTOF | splash10-001r-0101900000-9bc88a73c10df6bd0274 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Canertinib 20V, Positive-QTOF | splash10-0ue9-4905700000-6a2b9e59d45824ffac26 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Canertinib 40V, Positive-QTOF | splash10-0f9l-8965000000-9ed9a5902ba5708bb5c0 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Canertinib 10V, Negative-QTOF | splash10-053r-2103900000-4a44b2d4d4e47679dd4b | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Canertinib 20V, Negative-QTOF | splash10-0pc9-7109400000-bf1dd09ef0b9ba0d28dc | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Canertinib 40V, Negative-QTOF | splash10-0fk9-7398000000-78462c2dd1330e8d00c9 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Canertinib 10V, Positive-QTOF | splash10-000i-0000900000-357edfc8c1369d8b3666 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Canertinib 20V, Positive-QTOF | splash10-000i-0101900000-e404117d2ec78afffac7 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Canertinib 40V, Positive-QTOF | splash10-0udl-2309500000-867765aafe00e13d9b73 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Canertinib 10V, Negative-QTOF | splash10-001i-0000900000-4082b100d8f4ad7cd143 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Canertinib 20V, Negative-QTOF | splash10-001i-0006900000-1d1d07987279e29739fc | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Canertinib 40V, Negative-QTOF | splash10-0ziu-3019200000-830f0e86cfbae7d3e09c | 2021-10-12 | Wishart Lab | View Spectrum |
|
---|